← Back to Home

Locking Two Proteins Together: J&J’s Prostate Cancer Drug Shows Tumor Responses in 12 of 16 Patients in Early Trial

The oral investigational drug JNJ-6143 uses a RIPTAC mechanism to constrain a protein cancer cells need to survive, showing antitumor signals in patients who have received multiple treatments. But the 75% response rate comes from 16 patients; how long the effects last and whether the drug can extend life remain questions for further research.

By SURL BioNews

When prostate cancer continues to progress after multiple treatments, new drugs need to find another way to disrupt cancer cell survival. Phase 1 results released by Johnson & Johnson for its oral drug JNJ-6143 provide preliminary human evidence for a strategy of “locking two proteins together”: among 16 patients with measurable lesions in the 50 mg once-daily dose group, 12 had confirmed complete or partial responses.

The data were presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid and involved patients with metastatic castration-resistant prostate cancer. According to the company announcement and BioSpace reporting, participants had received a median of four prior treatments, including chemotherapy and radioligand therapy targeting prostate-specific membrane antigen (PSMA). This gives the results value for clinical exploration, while also reminding readers that the study describes a specific population of patients with advanced disease and cannot be directly generalized to all patients with prostate cancer.

The denominator behind the 75% figure is the 16 patients with measurable lesions on imaging, rather than all 38 patients in the 50 mg group. Another observation came from prostate-specific antigen (PSA) in the blood: the company reported that 77% of patients in that dose group had a confirmed PSA decline of at least 50%, while 48% had a decline of at least 90%. PSA changes and imaging responses provide treatment signals at different levels; neither can be directly equated with longer survival.

JNJ-6143, formerly known as HLD-0915, entered Johnson & Johnson’s development pipeline through its acquisition of Halda Therapeutics. Its RIPTAC mechanism uses the androgen receptor (AR), which is highly expressed in prostate cancer cells, to bring the BRD4 protein needed for cell survival into proximity and constrain it. According to the company’s explanation of the mechanism, this dual-protein binding design is intended to disrupt cancer cell function and induce cell death. These results support further testing of the concept but are not sufficient to establish its clinical advantage.

The primary tasks of the Phase 1 trial remain assessing safety and selecting a dose. BioSpace reported that among the 38 patients in the 50 mg group, four had dosing interruptions due to adverse events, one had a dose reduction, and one discontinued treatment. The company said most treatment-related adverse events were mild to moderate, with common events including elevated cholesterol, nausea, and elevated triglycerides. These data help provide a preliminary assessment of tolerability, but a small, early-stage trial cannot yet adequately characterize less common risks or those associated with long-term use.

Johnson & Johnson has selected 50 mg once daily as the preliminary optimal dose for further development, which includes another Phase 2 study. The central questions at this stage are how long tumor responses can last and whether patients can consequently achieve longer disease control and survival. These small-sample data have not established an efficacy advantage over existing treatments. Larger studies and longer follow-up are still needed to translate early responses into a reliable treatment option.

References

  1. Johnson & Johnson
  2. BioSpace
  3. Johnson & Johnson